Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.21% |
| 2 | Technology | 12.9% |
| 3 | Consumer Discretionary | 10.45% |
| 4 | Financials | 8.48% |
| 5 | Industrials | 7.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3101
SB Financial Group
SBFG
$171M
| $262K | ﹤0.01% |
13,965
+1,260
| +10% | +$21.3K |
|
3102
Yext
YEXT
$574M
| $262K | ﹤0.01% |
18,146
-1,246,745
| -99% | -$19.3M |
|
|
BVSN
3103
DELISTED
Broadvision Inc Com
BVSN
| $262K | ﹤0.01% |
100,500
+14,500
| +17% | +$38.5K |
|
|
GENE
3104
DELISTED
Genetic Technologies Ltd.
GENE
| $259K | ﹤0.01% |
26,062
+3,523
| +16% | +$34.4K |
|
3105
Solid Biosciences
SLDB
$972M
| $258K | ﹤0.01% |
3,869
+1,716
| +80% | +$189K |
|
|
CLSD
3106
DELISTED
Clearside Biomedical
CLSD
| $257K | ﹤0.01% |
+5,913
| New | +$124K |
|
3107
State Street SPDR S&P International Dividend ETF
DWX
$529M
| $257K | ﹤0.01% |
+6,400
| New | +$255K |
|
3108
Sol-Gel Technologies
SLGL
$234M
| $257K | ﹤0.01% |
1,499
-764
| -34% | -$66K |
|
|
AMRB
3109
DELISTED
American River Bankshares
AMRB
| $257K | ﹤0.01% |
17,302
+6,640
| +62% | +$96.9K |
|
3110
Palisade Bio
PALI
$375M
| $256K | ﹤0.01% |
58
+36
| +164% | +$180K |
|
3111
Sonoma Pharmaceuticals
SNOA
$6.56M
| $256K | ﹤0.01% |
2,935
+611
| +26% | +$61K |
|
3112
Cogent Biosciences
COGT
$6.76B
| $255K | ﹤0.01% |
88,615
+85,365
| +2,627% | +$348K |
|
3113
QuidelOrtho
QDEL
$1.02B
| $255K | ﹤0.01% |
3,400
-5,500
| -62% | -$355K |
|
3114
iShares ESG Optimized MSCI USA ETF
SUSA
$4.21B
| $255K | ﹤0.01% |
+3,800
| New | +$243K |
|
3115
Brink's
BCO
$4.69B
| $254K | ﹤0.01% |
+2,800
| New | +$247K |
|
3116
iShares International Developed Real Estate ETF
IFGL
$82.3M
| $254K | ﹤0.01% |
+8,415
| New | +$254K |
|
|
WHWK
3117
Whitehawk Therapeutics
WHWK
$269M
| $254K | ﹤0.01% |
27,142
+16,449
| +154% | +$137K |
|
|
NWHM
3118
DELISTED
THE NEW HOME COMPANY INC.
NWHM
| $254K | ﹤0.01% |
54,500
+2,600
| +5% | +$11.8K |
|
3119
Arcturus Therapeutics
ARCT
$223M
| $253K | ﹤0.01% |
23,300
-9,200
| -28% | -$96.3K |
|
3120
Lightpath Technologies
LPTH
$824M
| $253K | ﹤0.01% |
349,095
+98,680
| +39% | +$66.5K |
|
3121
Radiant Logistics
RLGT
$400M
| $253K | ﹤0.01% |
45,507
-120,993
| -73% | -$654K |
|
3122
Oak Valley Bancorp
OVLY
$283M
| $252K | ﹤0.01% |
+12,973
| New | +$230K |
|
|
GOLD
3123
Gold.com Inc
GOLD
$1.3B
| $251K | ﹤0.01% |
60,600
-1,000
| -2% | -$5.15K |
|
|
ASM
3124
Avino Silver & Gold Mines
ASM
$1.21B
| $251K | ﹤0.01% |
434,138
+107,831
| +33% | +$57.5K |
|
3125
Marten Transport
MRTN
$1.22B
| $249K | ﹤0.01% |
17,400
-52,350
| -75% | -$747K |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.